(Q37992256)

26 August 2017

title

Liraglutide: from clinical trials to clinical practice (English)

1 reference

26 August 2017

1 reference

S C L Gough

1

1 reference

26 August 2017

publication date

1 April 2012

1 reference

Diabetes, Obesity and Metabolism

26 August 2017

published in

1 reference

26 August 2017

volume

14 Suppl 2

1 reference

26 August 2017

page(s)

33-40

1 reference

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Liraglutide in oral antidiabetic drug combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Obesity and disease management: effects of weight loss on comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Standards of medical care in diabetes--2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

How does treatment satisfaction work?: Modeling determinants of treatment satisfaction and preference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Patient perceptions of diabetes and diabetes therapy: assessing quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Prevalence and control of dyslipidemia among persons with diabetes in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01576.X

10.1111/J.1463-1326.2012.01576.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference